Research information only. PrecisePep is an educational library. It is not medical advice and is not intended to assist, encourage or enable self-administration. The compounds documented here are research chemicals — most are not approved for human use. Read the full disclaimer.
PrecisePep/Peptide Library/Adamax
Neuro-Cognitive & Nootropic
adamantane-modified Semax analogue · adamantyl-Semax · ADA-Max
A Semax analogue with an adamantane cage bolted on for enzymatic stability and membrane permeability. Reported as markedly stronger than the parent — on an evidence base that is thinner than the parent, which is already thin in the West.
Adamax is what happens when a chemist takes a peptide that mostly works and tries to make it survive longer. It is Semax with an adamantane group attached — adamantane being a rigid, highly lipophilic cage hydrocarbon used across medicinal chemistry precisely because bolting it onto a molecule tends to increase metabolic stability and membrane permeability. The same trick appears in amantadine, memantine and rimantadine.
The rationale is straightforward. Semax already carries a Pro-Gly-Pro tail to resist peptidases, and it still has a short duration of action. Adding a lipophilic cage should slow degradation further and improve passage across membranes, including the blood–brain barrier. Suppliers describe Adamax in exactly those terms — enhanced enzymatic stability, BDNF expression and TrkB receptor sensitivity relative to unmodified Semax.[4]
The problem is that almost none of this has been published. Semax itself has a real if geographically narrow evidence base — a Russian registration, domestic clinical trials, and a solid BDNF/TrkB mechanistic literature. Adamax has essentially no independent literature of its own. Every claim about it is either inherited from Semax or asserted by the people selling it, and the community consensus that it is "much stronger" comes from users comparing subjective effects at doses nobody has calibrated.
"More potent than Semax" is the entire basis on which Adamax is dosed lower than Semax — with no published potency ratio to convert between them. If the modification raises both potency and duration, a microgram-for-microgram substitution is not equivalent in either dimension. The community's usual response, "use less", is a guess with the right instinct behind it and no number under it.
Inherited from Semax. The peptide backbone is unchanged, so the proposed mechanisms are the parent's: upregulation of BDNF and its receptor TrkB in hippocampus and frontal cortex, enhancement of dopaminergic transmission, inhibition of enkephalin-degrading enzymes, and melanocortin-related neuroprotection without corticotropic activity.[1][2]
What the adamantane adds — in theory. Adamantane conjugation is a well-established medicinal-chemistry strategy. The cage is bulky, rigid and strongly lipophilic, which typically slows enzymatic cleavage by sterically shielding the peptide and improves partition into lipid membranes. For a CNS-targeted peptide that means, in principle, a longer half-life and better brain penetration.[3]
What that does not guarantee. Increasing lipophilicity is not uniformly good. It can raise non-specific tissue binding, change the distribution profile, and alter which receptors a molecule reaches — a compound that penetrates better does not necessarily do more of the same thing, it may simply do different things in different places. None of this has been characterised for Adamax.
Route. Intranasal, as for Semax, exploiting nose-to-brain transport. Whether the increased lipophilicity meaningfully changes intranasal absorption for this molecule is unstudied.
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
There is no clinical trial, no animal study and no independent pharmacology paper for the adamantane-modified analogue. This row is here because its absence is the single most important fact on the page.
Semax is registered for ischaemic stroke, TIA, cognitive disorders and optic nerve conditions, with domestic clinical work behind it. Adamax inherits none of that registration and none of that data.
The best-corroborated mechanistic finding for Semax, demonstrated in rodent hippocampus and cortex. The backbone is unchanged in Adamax, so this is the most defensible inherited claim.
A general medicinal-chemistry literature supports adamantyl modification for improved metabolic stability and membrane permeability across many molecule classes. That is a class principle, not a finding about this peptide.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The primary design rationale, following directly from reduced enzymatic degradation. Plausible and unmeasured — no pharmacokinetic profile has been published for Adamax.
The other half of the design rationale. Increased lipophilicity generally improves CNS penetration; whether it does so here, and by how much, has not been measured.
Asserted in supplier literature and echoed throughout the research community. If the compound reaches the brain in higher concentration for longer, a larger downstream effect follows — but the inference chain is entirely unvalidated.
Brain fog clearance, focus, mood, neuroprotection under stress. Every one is an extrapolation from Semax, which is itself extrapolating from clinical populations to healthy adults.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The near-universal community report and the reason Adamax exists as a product. Users describe a sharper onset, a more pronounced effect, and a longer active window — often several hours beyond what they get from Semax.
The circulating protocol specifies 500 mcg Semax in the morning, "or Adamax if you want a stronger effect" — at the same figure, with no dose adjustment stated.
Most reports use 100–300 mcg against 300–600 mcg for Semax — a reduction driven entirely by subjective potency comparison, not by any established ratio. Note this contradicts the protocol above, which uses the same figure for both.
The commonest complaint, and the expected consequence if the compound really is more potent and longer-acting: the same afternoon cutoff that works for Semax is reported as insufficient here.
Users who pair Semax with Selank report the counterweight matters more with Adamax. Consistent with a stronger activating stimulus.
There is no widely recognised reference standard for "Adamax". What a vial contains, and whether two suppliers are selling the same molecule, is not something a buyer can establish from a purity assay alone.
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No toxicology, no pharmacokinetics, no clinical safety review, no adverse-event surveillance. Not thin data — no data.
Semax has a benign profile in Russian registered use. A modified analogue with different lipophilicity, different distribution and different duration is a different compound, and the parent safety record is not inherited by chemistry alone.
Adamantane-containing drugs (amantadine, memantine) are CNS-active in their own right, with dopaminergic and NMDA-receptor effects. Whether a conjugated adamantyl group contributes any independent activity here is uncharacterised — but assuming it is inert is an assumption.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
If the modification genuinely extends duration, daily dosing at Semax-like intervals produces accumulation that Semax does not. Nobody using it knows the half-life, so nobody can know whether this is happening.
Better membrane penetration means reaching tissues and receptors the parent compound does not. That is the point of the modification and also the risk of it.
Every unknown about sustained pharmacological BDNF elevation applies here with a compound designed to do more of it for longer.
Dopaminergic modulation layered onto stimulants, SSRIs or antipsychotics is uncharacterised for Semax and doubly so for a more potent analogue.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The dominant complaint, more prominent than with Semax and usually resolved by reducing dose or moving it earlier.
Reported at times of day that Semax users tolerate, which is itself indirect evidence for the longer-duration claim.
As for any intranasal peptide.
Reported at higher doses or after several consecutive days without a break.
Reported by some users over two to three weeks of daily use.
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No study, no registration, no clinical use. Every figure in circulation is derived from subjective comparison with Semax.
The Russian registered product is supplied as 0.1% and 1% intranasal drops with defined dosing for stroke and cognitive indications — the only anchored dosing anywhere near this compound.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
If the compound is genuinely more potent and longer-acting, the conservative substitution is a fraction of the Semax figure rather than a like-for-like swap. This is the one point where community practice and cautious reasoning agree.
A longer duration means the afternoon cutoff that works for the parent is not sufficient here. Morning-only is the coherent position.
If duration is genuinely extended, daily dosing may be more than the pharmacology requires — every-other-day use is a defensible inference nobody has tested.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The dominant community range, roughly a third to a half of typical Semax dosing.
The circulating protocol offers Adamax as a direct substitute for Semax at the same 500 mcg figure, one vial (about 20 days) on, then an equal period off. That is at the top of — or above — the range most users report.
The pairing convention carries over from Semax, and is reported as mattering more here.
Used by some to manage the reported faster tolerance build. Coherent with a longer half-life; undocumented.
| Approach | Dose | Route | Timing |
|---|---|---|---|
| Conservative substitution | 100 – 200 mcg | Intranasal | Morning only |
| Standard community | 200 – 300 mcg | Intranasal | Morning only |
| Gold Standard Protocol | 500 mcg | Intranasal | Morning, never after 2pm |
| Semax, for comparison | 300 – 600 mcg | Intranasal | Morning, never after 2pm |
Community practice halves the Semax dose for Adamax on potency grounds. The widely circulated protocol substitutes it one-for-one at 500 mcg. Both cannot be right, and no published potency ratio exists to settle it. That disagreement — sitting unremarked inside the most-shared peptide protocol in circulation — is a fair summary of how much is actually known about this compound.
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No study has combined Adamax with anything.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The Semax pairing carried over: dopaminergic drive with a GABAergic counterweight on a shared BDNF substrate. If Adamax really is the stronger stimulus, the argument for the counterweight is stronger too.
Running both is redundant at best — the same backbone acting on the same receptors — and doubles an unquantified exposure at worst.
Proposed on the premise that neuronal energy availability limits cognitive benefit. Speculative for Semax and more so here.
The commonest source of overstimulation reports with Semax, and reported as worse with Adamax.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The standard use — Adamax replaces the Semax component, Selank stays.
Some users keep both and reserve Adamax for demanding days while running Semax otherwise. No basis beyond preference.
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
There is no trial, registration or published protocol for this compound.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Start at a fraction of the parent dose, morning only, with a defined short course — because none of the parent safety record actually transfers.
The Semax convention, with more reason behind it here given the reported faster tolerance build.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
500 mcg in the morning, never after 2pm, always with Selank. One vial (about 20 days) on, then off for an equal period.
The general community pattern, sometimes shortened relative to Semax because of the reported faster tolerance.
This section is shorter than the others in this library, and the reason is the finding. Adamax is sold for cognition, focus and mood, and there is no published literature on it under that name for any of them. What follows is an account of what is actually known, which is mostly an account of what is being assumed.
"Adamax" is a market name, not a research name. It does not correspond to a compound with its own published literature, and searching for it returns supplier pages rather than papers. It is generally described as a Semax-family analogue, and every claim made for it is a read-across from Semax — which itself has no Western trial evidence. That is a claim built on a claim.
Pathophysiology
Not a condition. Everything below depends on this and it is rarely addressed.
Mechanistic rationale
Before asking whether a compound works for something, it is worth being able to say what it is. Adamax is presented as a modified Semax analogue, and the specific modification varies between descriptions. A structural modification is not a cosmetic detail — the difference between DAC and no-DAC CJC-1295 changes a pulse into a plateau, and the difference between full-length thymosin beta-4 and TB-500 is the difference between clinical-stage trial evidence and none. Assuming an analogue inherits a parent compound’s properties is exactly the assumption those two examples disprove.
Community reports
Vendor descriptions are consistent with each other and inconsistent with the absence of any primary source, which usually indicates copying rather than independent knowledge.
Components carrying the argument: Unresolved
Pathophysiology
Attention and working memory depend on prefrontal catecholamine signalling; consolidation depends on hippocampal plasticity and, substantially, on sleep.
Mechanistic rationale
The proposed mechanism is the Semax one — BDNF and monoaminergic modulation — borrowed wholesale. If the read-across holds, the ceiling is whatever Semax does, and Semax’s own evidence is a small, local, largely non-randomised literature. If the read-across does not hold, nothing is known at all.
Community reports
Reports describe focus and verbal fluency, in the same register as every other nootropic. These are the most placebo-responsive endpoints in this library, self-assessed by the person taking the compound, usually within days of starting something they paid for and expected to work.
Components carrying the argument: Assumed BDNF and monoaminergic effects
Pathophysiology
Reduced BDNF signalling is one of the more durable findings in depression research.
Mechanistic rationale
Same read-across, same limits. Worth noting that a rapid subjective mood lift — which is what gets reported — arrives faster than any BDNF-mediated mechanism plausibly acts, which is informative about what is producing the report.
Community reports
Frequently described as more stimulating than Semax. That comparison is made by users, not by any study, and stimulation is among the easiest effects to generate by expectation.
Components carrying the argument: Assumed
Pathophysiology
Not a condition.
Mechanistic rationale
A compound with no literature is not automatically ineffective — it is unassessed, which is a different thing and an honest one to state. What it does mean is that there is no basis for a dose, no characterised adverse effect profile, no drug interaction information and no way to tell a supplier’s product from anything else in a vial. Of everything in this library, this is the compound where "third-party analysis" moves from advisable to load-bearing, because identity is the open question rather than purity.
Community reports
Nobody reporting on this compound has independently confirmed what they received.
Components carrying the argument: —
| Question | Position |
|---|---|
| Published literature under this name? | None found |
| What is it? | Described as a Semax-family analogue; specifics vary by vendor |
| Does an analogue inherit the parent evidence? | No — see DAC/no-DAC and TB-500 vs Tβ4 |
| Best case | Whatever Semax does — itself a small local literature |
| Worst case | Unknown compound, unknown dose, unknown profile |
| What matters most | Identity confirmation, not purity |
For cognition: sleep is the intervention with the largest and most reliable effect on attention, working memory and consolidation, and it is the one most often traded away by the people buying nootropics. Physical activity, treating hearing loss, managing blood pressure in midlife, and not smoking are the evidenced list for long-term cognitive health. For diagnosed ADHD, the stimulants have among the largest effect sizes in psychiatry — and an assessment costs less than a year of unassessed peptides.
For mood: cognitive behavioural therapy, SSRIs and SNRIs, exercise, and treatment of alcohol use where present. If symptoms include thoughts of self-harm, that is an emergency and belongs with a person rather than a vial.
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
Supplied lyophilised, commonly 10 mg per vial. For intranasal use the reconstituted solution is transferred to a nasal spray bottle — a step that introduces sterility and dose-accuracy problems the injectable route does not have. At 300 mcg daily a 10 mg vial is over a month.
Lyophilised: refrigerated or frozen. Reconstituted: 2–8 °C. Nasal spray bottles in daily use are a contamination risk and are typically replaced between vials.
Commonly 10 mg lyophilised vials.
The adamantyl modification is intended to improve enzymatic stability in vivo; that says nothing about stability in a refrigerated vial, which is governed by the same handling considerations as any peptide.
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Not approved anywhere, and not registered even where the parent is. Semax holds a Russian registration; Adamax does not, in Russia or anywhere else. It is sold exclusively as a research chemical.
This is a meaningful distinction. A reader might reasonably assume an analogue inherits its parent's standing. It does not — not regulatory standing, not clinical data, not a safety record.
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: still no published literature under this name — the finding itself. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Athletes subject to WADA, USADA, UKAD, NCAA or military testing should assume any peptide is prohibited unless they have verified otherwise against the current WADA Prohibited List. Several classes here (growth-hormone secretagogues, TB-4 analogues, metabolic modulators) are explicitly named. Check the current list — it is republished annually.
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.
